AgNavigator reports on BiomEdit’s acquisition of Folium Science, with independent reporting and direct quotes from CEO Aaron Schacht. According to the report, Folium’s CRISPR-Cas team will stay on as advisors, BiomElix® One and CPerf LLV* (BE-101) are on track for simultaneous 2027 launches in Brazil, and BiomEdit still plans to pursue a Series C financing round following CPerf LLV* (BE-101)‘s USDA licensure.
Source: AgNavigator
